WO2019178472A1 - Utilisation d'inhibiteurs d'oxydation d'acides gras comme agents antimicrobiens - Google Patents

Utilisation d'inhibiteurs d'oxydation d'acides gras comme agents antimicrobiens Download PDF

Info

Publication number
WO2019178472A1
WO2019178472A1 PCT/US2019/022457 US2019022457W WO2019178472A1 WO 2019178472 A1 WO2019178472 A1 WO 2019178472A1 US 2019022457 W US2019022457 W US 2019022457W WO 2019178472 A1 WO2019178472 A1 WO 2019178472A1
Authority
WO
WIPO (PCT)
Prior art keywords
set forth
fao
inhibitor
etomoxir
administering
Prior art date
Application number
PCT/US2019/022457
Other languages
English (en)
Inventor
Jennifer A. PHILIPS
Kathryn MOORE
Pallavi CHANDRA
Mireille OUIMET
Original Assignee
Washington University In St. Louis
New York University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University In St. Louis, New York University filed Critical Washington University In St. Louis
Priority to US16/979,443 priority Critical patent/US11717519B2/en
Publication of WO2019178472A1 publication Critical patent/WO2019178472A1/fr
Priority to US18/338,717 priority patent/US20240000774A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Chemistry (AREA)

Abstract

L'invention concerne des méthodes d'utilisation d'inhibiteurs à petites molécules d'oxydation d'acides gras (FAO) comme agents antimicrobiens contre des mycobactéries intracellulaires. Des inhibiteurs de FAO comprenant de l'étomoxir, de la trimétazidine, de l'oxfénicine, de la perhexiline et/ou peuvent être utilisés seuls ou en association avec des agents anti-mycobactériens connus contre des mycobactéries intracellulaires.
PCT/US2019/022457 2017-04-21 2019-03-15 Utilisation d'inhibiteurs d'oxydation d'acides gras comme agents antimicrobiens WO2019178472A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US16/979,443 US11717519B2 (en) 2017-04-21 2019-03-15 Use of fatty acid oxidation inhibitors as antimicrobials
US18/338,717 US20240000774A1 (en) 2017-04-21 2023-06-21 Use of fatty acid oxidation inhibitors as antimicrobials

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862644105P 2018-03-16 2018-03-16
US62/644,105 2018-03-16

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/979,443 A-371-Of-International US11717519B2 (en) 2017-04-21 2019-03-15 Use of fatty acid oxidation inhibitors as antimicrobials
US18/338,717 Continuation US20240000774A1 (en) 2017-04-21 2023-06-21 Use of fatty acid oxidation inhibitors as antimicrobials

Publications (1)

Publication Number Publication Date
WO2019178472A1 true WO2019178472A1 (fr) 2019-09-19

Family

ID=67906925

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/022457 WO2019178472A1 (fr) 2017-04-21 2019-03-15 Utilisation d'inhibiteurs d'oxydation d'acides gras comme agents antimicrobiens

Country Status (1)

Country Link
WO (1) WO2019178472A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070148689A1 (en) * 2000-04-03 2007-06-28 Kathryn Leishman Compositions and methods for the prevention, treatment and detection of tuberculosis and other diseases
US20100137192A1 (en) * 2003-08-26 2010-06-03 Leland Shapiro Compositions and methods for treating or ameliorating mycobacterial infections
US20150258047A1 (en) * 2011-04-11 2015-09-17 Akthelia Pharmaceuticals Therapeutic Compounds
US9655958B2 (en) * 2005-04-29 2017-05-23 Glaxosmithkline Biologicals Sa Method for preventing or treating M tuberculosis infection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070148689A1 (en) * 2000-04-03 2007-06-28 Kathryn Leishman Compositions and methods for the prevention, treatment and detection of tuberculosis and other diseases
US20100137192A1 (en) * 2003-08-26 2010-06-03 Leland Shapiro Compositions and methods for treating or ameliorating mycobacterial infections
US9655958B2 (en) * 2005-04-29 2017-05-23 Glaxosmithkline Biologicals Sa Method for preventing or treating M tuberculosis infection
US20150258047A1 (en) * 2011-04-11 2015-09-17 Akthelia Pharmaceuticals Therapeutic Compounds

Similar Documents

Publication Publication Date Title
Bailo et al. Lipid transport in Mycobacterium tuberculosis and its implications in virulence and drug development
Thuita et al. Efficacy of the diamidine DB75 and its prodrug DB289, against murine models of human African trypanosomiasis
US10004744B2 (en) Therapeutic approaches for treating Parkinson's disease
Hegeto et al. In vitro combinatory activity of piperine and anti-tuberculosis drugs in Mycobacterium tuberculosis
WO2005070080A2 (fr) Procedes d'utilisation de zonisamide comme therapie auxiliaire pour des crises partielles
BRPI0616659A2 (pt) droga terapÊutica antituberculose, medicamento, e, kit para o tratamento de tuberculose
WO2005020903A2 (fr) Methodes permettant d'ameliorer la securite d'une therapie par le zonisamide
MX2012001814A (es) Uso de 4-aminopiridina para mejorar la discapacidad neuro - cognoscitiva y/o neuro - psiquiatrica en pacientes con condiciones desmielizantes y otras condiciones del sistema nervioso.
JPWO2008090736A1 (ja) アルツハイマー型認知症の予防及び治療のための医薬
Wammack et al. Efficacy of oral doxepin and piroxicam treatment for interstitial cystitis
Dunne et al. A phase 1 study to assess the pharmacokinetics of sulopenem etzadroxil (PF-03709270)
KR20120050512A (ko) 탈수초를 갖는 환자에서 ４-아미노피리딘을 사용한 지속적 치료
US11717519B2 (en) Use of fatty acid oxidation inhibitors as antimicrobials
Johnkennedy et al. Alterations in biochemical parameters of Wister rats administered with sulfadoxine and pyrimethamine (Fansidar R)
RU2472512C1 (ru) Противотуберкулезная композиция и способ ее получения
WO2019178472A1 (fr) Utilisation d'inhibiteurs d'oxydation d'acides gras comme agents antimicrobiens
Mimi et al. Tuberculosis and chronic renal failure; therapy patterns
US20220395495A1 (en) Shortening tuberculosis therapy and reducing relapse by co-administering chloroquine in tb and hiv-tb coinfected conditions
JP6454436B1 (ja) ペマフィブラートを含有する医薬
JP2007503425A (ja) 哺乳動物における中毒の予防及び治療のための医薬組成物
RU2523792C9 (ru) Лекарственное средство для лечения туберкулеза
US20230014055A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
JP2018507216A (ja) 多発性骨髄腫に対するパノビノスタット投与量
Das et al. Delamanid and its role in drug-resistant tuberculosis
Mistry et al. New drugs for tuberculosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19767981

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19767981

Country of ref document: EP

Kind code of ref document: A1